60 Degrees Pharmaceuticals logo
60 Degrees Pharmaceuticals
SXTP | NASDAQ
Chart Builder DCF Calculator
$0.49
-$0.03 (-5.39%)
At close: Nov 16, 2026, 4:00 PM ET
$0.51
+$0.02 (+4.35%)
After-hours: Nov 16, 2026, 7:33 PM ET

60 Degrees Pharmaceuticals Company Profile

Company profile explained

Company Profile

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.

Key Executives

Name Position
Geoffrey Stuart Dow Chairman, Chief Executive Officer & President
Tyrone Miller Chief Financial Officer
Bryan Smith Chief Medical Officer
Kristen Landon Chief Commercial Officer

Latest SEC Filings

Date Type Title
Oct 27, 2026 8-K Current Report
Oct 23, 2026 8-K Current Report
Oct 06, 2026 8-K Current Report
Sep 14, 2026 8-K Current Report
Sep 08, 2026 8-K Current Report
Aug 25, 2026 EFFECT Filing
Aug 17, 2026 DEL AM Filing
Aug 14, 2026 S-3 Filing
Aug 14, 2026 10-Q Quarterly Report
Aug 06, 2026 8-K Current Report
View All SEC Filings ➞
60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals logo
Country United States
IPO Date Jul 12, 2023
Industry Biotechnology
Sector Healthcare
Employees 3
CEO Geoffrey Stuart Dow

Contact Details

1025 Connecticut Avenue NW Washington, DC 20036 United States

Stock Details

Ticker Symbol SXTP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001946563
CUSIP Number 83006G500
ISIN Number US83006G5009
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.